Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 4/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.43 |
| ▸ | DRD1 | P21728 | 4/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.43 |
| ▸ | HTR2A | P28223 | 3/20 | 0.43 |
| ▸ | HRH1 | P35367 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | HTR2C | P28335 | 2/20 | 0.43 |
| ▸ | HTR2B | P41595 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10605561 | 0.80 | CYP2D6 (0.47) | CYP2D6CYP2C19CHRM2ADRA2ADRD1 | |
| SCHEMBL7752752 | 0.79 | CYP2D6 (0.52) | CYP2D6CYP2C19CHRM2ADRA2ADRD1 | |
| SCHEMBL5778326 | 0.77 | CYP2D6 (0.44) | CYP2D6CYP2C19CHRM2ADRA2ADRD1 | |
| SCHEMBL231127 | 0.77 | CYP2D6 (0.57) | CYP2D6CYP2C19CHRM2ADRA2ADRD1 | |
| SCHEMBL364 | 0.77 | — | — | |
| SCHEMBL29635663 | 0.77 | — | — | |
| Bromide SCHEMBL2900871 | 0.75 | CYP2D6 (0.55) | CYP2D6CYP2C19CHRM2ADRA2ADRD1 | |
| Bromide SCHEMBL3252964 | 0.75 | CYP2D6 (0.55) | CYP2D6CYP2C19CHRM2ADRA2ADRD1 | |
| SCHEMBL6260224 | 0.75 | CYP2D6 (0.55) | CYP2D6CYP2C19CHRM2ADRA2ADRD1 | |
| Hydrochloric Acid SCHEMBL6775520 | 0.75 | CYP2D6 (0.55) | CYP2D6CYP2C19CHRM2ADRA2ADRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2770977-B1 | NOVEL DOSAGE FORM | NEUROVIVE PHARMACEUTICAL AB (SE) | 2017-07-12 | — | — | EP | disclosed |
| US-9504728-B2 | Dosage form | NEUROVIVE PHARMACEUTICAL AB (SE) | 2016-11-29 | — | — | US | disclosed |
| US-9119853-B2 | Sanglifehrin based compounds | NEUROVIVE PHARMACEUTICAL AB (SE) | 2015-09-01 | — | — | US | disclosed |
| US-20140234414-A1 | Novel Dosage Form | Abliva Ab (SE) | 2014-08-21 | — | — | US | disclosed |
| WO-2013061052-A1 | NOVEL DOSAGE FORM | BIOTICA TECHNOLOGY LIMITED (GB) | 2013-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140234414-A1 | Novel Dosage Form | SI, RAB10, SAMM50 | CYP2D6 252/4885CYP2C19 248/4885CHRM2 4192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.